Nav: Home

New reversible drug shows early promise in preventing dangerous clots

December 17, 2015

DALLAS, Dec. 17, 2015 - A new drug that protects against dangerous blood clots in patients undergoing procedures such as angioplasty to restore blood flow through the coronary arteries, appears safe, fast, and the effects are uniquely reversible, according to early testing described in the American Heart Association journal: Arteriosclerosis, Thrombosis and Vascular Biology.

Antiplatelet drugs currently available to patients carry an increased risk of bleeding. If a patient needs surgery while taking these medications, they may have a greater risk of complications due to blood loss. The new antiplatelet drug called PZ-128 is unique because it acts quickly to prevent dangerous blood clots from forming during a coronary artery procedure and its effects are reversible, reducing the risk of excess bleeding.

PZ-128 is a new type of drug called a pepducin. Pepducins enter cells and, from the interior side of the cell membrane, act on a specific receptor that alter the cell's biochemical processes.

This study is the first demonstration of pepducin's potential benefits in humans, said Athan Kuliopulos, M.D., Ph.D., senior author of the study and director of the Center for Hemostasis and Thrombosis Research at Tufts Medical Center in Boston, Massachusetts.

The new drug was given to 31 patients, ages 43 to 74, in a range of doses. More than one-fifth of the patients had coronary artery disease; the rest had risk factors for coronary artery plaques such as high blood pressure, cholesterol, diabetes or smoking. Many of the patients were taking medicines for heart disease including aspirin, or drugs to control blood pressure, cholesterol or blood glucose.

Researchers found that the more PZ-128 a patient received, the better the medicine blocked platelet aggregation -- the clumping together of platelets in the blood which can lead to deadly clots. At the highest doses, PZ-128 prevented 80 percent to 100 percent of platelets from clumping together. Moreover, the impact of the PZ-128 was quickly reversed, with the drug completely clearing patients' blood as early as 24 hours (and at least up to 192 hours) after it was given.

Current antiplatelet therapy commonly takes a two-pronged approach, with aspirin and a class of medicines that includes clopidogrel acting in two different ways to inhibit platelet clumping. Yet even with highly potent antiplatelet drugs, about 20 percent of patients suffer recurrent artery blockages within two years, Kuliopulos said, suggesting that aiming at yet another target could further reduce risk.

PZ-128 targets a platelet-activating receptor called PAR1. Blocking PAR1 on the cell's outer surface has been challenging because at that site the receptor is very similar to receptors for related molecules. But that's not the case where PZ-128 acts on the receptor, inside the cell. Currently, no drugs are on the market for blocking PAR1 during procedures when the risk of serious complications like a heart attack is high.

A PAR1-inhibiting pill, vorapaxar, is available for non-acute use in patients who previously had a heart attack or have peripheral artery disease. But the drug, whose effects build slowly and are long-lasting, was not approved for use during cardiac procedures due to a risk of excessive bleeding, Kuliopulos said. By contrast, PZ-128 appears able to block PAR1 fast enough to be used in an urgent procedure, and for a time short enough to limit bleeding risk afterward, he said.

Researchers cautioned that the research is only a Phase 1 study, whose main goals are gauging the drug's safety and finding tolerable doses. PZ-128 requires more testing before firm conclusions could be drawn about how well it works, he said. The research team is planning a Phase 2 study in up to 600 patients having angioplasty or with acute blockages of blood flow to the heart.
-end-
Co-authors are Paul A. Gurbel, M.D.; Kevin P. Bliden, M.B.A.; Susan E. Turner, B.S.; Udaya S. Tantry, Ph.D.; Martin G. Gesheff, B.S.; Travis P. Barr, Ph.D.; and Lidija Covic, Ph.D. Author disclosures are on the manuscript.

The National Heart, Lung, and Blood Institute funded the study.

Additional Resources:

Medication image, heart graphic, and full clot blockage animation are located in the right column of this release link http://newsroom.heart.org/news/new-reversible-drug-shows-early-promise-in-preventing-dangerous-clots?preview=dfa3fc381d3fd06fb555c1bb8cd2e8fe

Follow AHA/ASA news on Twitter @HeartNews.

For the updates and new science from the Arteriosclerosis, Thrombosis and Vascular Biology journal follow @atvbahajournals.

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.

American Heart Association

Related Heart Attack Articles:

Where you live could determine risk of heart attack, stroke or dying of heart disease
People living in parts of Ontario with better access to preventive health care had lower rates of cardiac events compared to residents of regions with less access, found a new study published in CMAJ (Canadian Medical Association Journal).
Activated T-cells drive post-heart attack heart failure
Chronic inflammation after a heart attack can promote heart failure and death.
ICU care for COPD, heart failure and heart attack may not be better
Does a stay in the intensive care unit give patients a better chance of surviving a chronic obstructive pulmonary disease (COPD) or heart failure flare-up or even a heart attack, compared with care in another type of hospital unit?
Heart attack treatment might be in your face
Researchers at the University of Cincinnati have received $2.4 million in federal funding to pursue research on a novel cell therapy that would repair heart damage using modified cells taken from the patient's own facial muscle.
Tissue engineering advance reduces heart failure in model of heart attack
Researchers have grown heart tissue by seeding a mix of human cells onto a 1-micron-resolution scaffold made with a 3-D printer.
Study shows functional effects of human stem cell delivery to heart muscle after heart attack
Researchers delivered human stem cells seeded in biological sutures to the damaged heart muscles of rats following induced acute myocardial infarction and assessed the effects on cardiac function one week later.
Younger heart attack survivors may face premature heart disease death
For patients age 50 and younger, the risk of premature death after a heart attack has dropped significantly, but their risk is still almost twice as high when compared to the general population, largely due to heart disease and other smoking-related diseases The risk of heart attack can be greatly reduced by quitting smoking, exercising and following a healthy diet.
After the heart attack: Injectable gels could prevent future heart failure (video)
During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells in the heart.
Heart failure after first heart attack may increase cancer risk
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a study today in the Journal of the American College of Cardiology.
1 in 4 patients develop heart failure within 4 years of first heart attack
One in four patients develop heart failure within four years of a first heart attack, according to a study in nearly 25,000 patients presented today at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure by Dr.

Related Heart Attack Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#513 Dinosaur Tails
This week: dinosaurs! We're discussing dinosaur tails, bipedalism, paleontology public outreach, dinosaur MOOCs, and other neat dinosaur related things with Dr. Scott Persons from the University of Alberta, who is also the author of the book "Dinosaurs of the Alberta Badlands".